ADELL WINLEY: Open Payments
NPI 1154546232 · SILVER SPRING, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,976 in 126 payments from 18 companies in 2025. Trend: 2023 $1,928 · 2024 $1,482 · 2025 $2,976
Food & beverage: $2,976
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 12 | $709 |
| ABBVIE INC. | 18 | $432 |
| PFIZER INC. | 23 | $357 |
| Ipsen Biopharmaceuticals, Inc | 10 | $307 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 21 | $215 |
| Madrigal Pharmaceuticals | 7 | $186 |
| Ardelyx, Inc. | 7 | $159 |
| GENZYME CORPORATION | 5 | $141 |
| QOL Medical, LLC | 5 | $113 |
| Gilead Sciences, Inc. | 3 | $64 |
Products named: TREMFYA, IQIRVO, XIFAXAN, REZDIFFRA, VELSIPITY, XELJANZ, RINVOQ, IBSRELA.
Industry payments across MD — which companies pay providers there.
